Sugary Drinks Cancer Risk: Women Face Higher Oral Cavity Cancer Threat

By João L. Carapinha

April 17, 2025

Recent research published in JAMA Otolaryngology-Head & Neck Surgery reveals a concerning link between sugary drinks and cancer risk. Women who consume at least one sugar-sweetened beverage per week face a nearly fivefold increased risk of developing oral cavity cancer (OCC) compared to those who drink such beverages less than once a month. This elevated risk persists regardless of other lifestyle factors, indicating a potential independent association between sugary drink consumption and OCC in women.

Strong Correlation Identified

The study analyzed a large cohort of 162,602 women and discovered a striking correlation. Women consuming at least one sugary beverage per week had a 4.87 times higher risk of OCC. Among nonsmokers and non-drinkers, daily sugary drink consumption was associated with a 5.46 times higher risk. This research highlights sugary beverages as a “modifiable risk factor” for OCC, adding to traditional risk factors like tobacco, alcohol, and HPV. It suggests that inflammation and microbiome changes, driven by high sugar intake, may contribute to cancer risk.

Although the study does not confirm causality, its findings are significant. The rising incidence of oral cavity cancer among non-smoking women globally cannot be fully explained by traditional risk factors. According to the American Cancer Society, almost 60,000 new cases of oral cavity and oropharyngeal cancers are expected in the U.S. in 2025. Historically, OCC has been more common in men and tobacco or alcohol users. However, its incidence is now increasing among women without these risk factors.

Global Health Advisory on Sugar Consumption

The World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) have long warned about the health risks of excessive sugar intake. Sugary beverages are linked to obesity, diabetes, and cardiovascular diseases. The CDC also emphasizes that sugar contributes to oral diseases, which are risk factors for oral cancers. Concerns about sugary drinks are growing as consumption rates rise worldwide, not only due to metabolic and cardiovascular risks but also for potentially raising cancer risks.

Economic Ramifications and Strategic Approaches

The heightened OCC risk linked to sugary beverages suggests greater future healthcare costs. Targeting sugary drink consumption as a prevention strategy could alleviate the economic burden of OCC. Furthermore, identifying sugary drinks as a modifiable risk factor provides a new focus for public health initiatives. Increased research is essential to confirm causality and evaluate risk in broader populations, including men.

Proposed regulatory measures to limit access to sugary beverages could be warranted. These include taxes, warning labels, and age restrictions. This shift may significantly impact the beverage industry. Also, insurers and health systems may expand coverage for nutritional counseling, preventive dental care, and risk screening for high-risk individuals.

Conclusion: A Shift in Prevention Strategies

In conclusion, this research emphasizes the need to focus on dietary factors—specifically sugary drink intake—when developing cancer prevention strategies. This shift could greatly influence public health policy and clinical decision-making. To explore more on this topic, you can access the detailed findings in the original JAMA Otolaryngology article here.

Reference url

Recent Posts

Innovations in Haematology Cell Therapy at ASH 2025

By HEOR Staff Writer

December 5, 2025

Advancing Haematology Cell Therapy Innovations at ASH 2025 AstraZeneca is significantly advancing haematology cell therapy with its largest-ever presence at the 67th American Society of Hematology (ASH) Annual Meeting and E...
Advancing EU Health Technology Assessment: Key Priorities in the HTACG Draft Annual Work Programm...

By João L. Carapinha

December 4, 2025

How will the EU Health Technology Assessment framework evolve in 2026 to improve clinical evaluations for cancer treatments and advanced therapies? The EU Health Technology Assessment (HTA) initiative coordinates standardized reviews of medicines and devices across Member States, thereby boosting...
WHO Guidelines Set New Standard for GLP-1 Obesity Therapies in Adults
What does the latest WHO guideline reveal about GLP-1 obesity therapies, as released in December 2025? This landmark document establishes the first global standards for integrating glucagon-like peptide-1 (GLP-1) receptor agonists and GIP/GLP-1 dual agonists into chronic obesity management, treat...